Muñoz, PDe la Villa, SMartínez-Sellés, MGoenaga, M AReviejo-Jaka, KRevillas, F Arnáiz de LasGarcía-Cuello, LHidalgo-Tenorio, CRodríguez-Esteban, M AAntorrena, ICastelo-Corral, LGarcía-Vázquez, EDe la Torre, JBouza, ESpanish Collaboration on Endocarditis- Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES)2025-01-072025-01-072021https://hdl.handle.net/10668/26476Current data on the frequency and efficacy of linezolid (LNZ) in infective endocarditis (IE) are based on small retrospective series. We used a national database to evaluate the effectiveness of LNZ in IE.This is a retrospective study of IE patients in the Spanish GAMES database who received LNZ. We defined 3 levels of therapeutic impact: LNZ  50% of the total treatment, and > 50% of the LNZ doses prescribed in the first weeks of treatment), and LNZ ≥ 7 days not fulfilling the high-impact criteria (LNZ-NHI). Effectiveness of LNZ was assessed using propensity score matching and multivariate analysis of high-impact cases in comparison to patients not treated with LNZ from the GAMES database matched for age-adjusted comorbidity Charlson index, heart failure, renal failure, prosthetic and intracardiac IE device, left-sided IE, and Staphylococcus aureus. Primary outcomes were in-hospital mortality and one-year mortality. Secondary outcomes included IE complications and relapses.From 3467 patients included in the GAMES database, 295 (8.5%) received LNZ. After excluding 3 patients, 292 were grouped as follows for the analyses: 99 (33.9%) patients in LNZ  50% of the LNZ doses prescribed in the first weeks of treatment), and LNZ ≥ 7 days not fulfilling the high-impact criteria (LNZ-NHI). Effectiveness of LNZ was assessed using propensity score matching and multivariate analysis of high-impact cases in comparison to patients not treated with LNZ from the GAMES database matched for age-adjusted comorbidity Charlson index, heart failure, renal failure, prosthetic and intracardiac IE device, left-sided IE, and Staphylococcus aureus. Primary outcomes were in-hospital mortality and one-year mortality. Secondary outcomes included IE complications and relapses.From 3467 patients included in the GAMES database, 295 (8.5%) received LNZ. After excluding 3 patients, 292 were grouped as follows for the analyses: 99 (33.9%) patients in LNZ enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/AgedAnti-Bacterial AgentsEndocarditisEndocarditis, BacterialFemaleHospital MortalityHumansLinezolidMaleMiddle AgedRetrospective StudiesStaphylococcal InfectionsStaphylococcus aureusTreatment Outcomeresearch article34941026open access10.1097/MD.00000000000275971536-5964PMC8701757https://doi.org/10.1097/md.0000000000027597https://pmc.ncbi.nlm.nih.gov/articles/PMC8701757/pdf